Table 10 Genotype frequencies of four polymorphisms in ONFH patients in the relation to number of affected joints (total, unilateral and bilateral ONFH) and controls
Genotype | Controls N=100 | Patients | ||
|---|---|---|---|---|
Total N=68 | Unilateral n=29 | Bilateral n=39 | ||
Factor V Leiden | ||||
GA | 3(3%) | 3(4,41%) | 2(6,89%) | 1(2,56%) |
GG | 97(97%) | 65(95,59%) | 27(93,11%) | 38(97,44%) |
Prothrombin | ||||
GA | 2(2%) | 1(1,47%) | 1(3,44%) | 0 |
GG | 98(98%) | 67(98,53%) | 28(96,56%) | 39(100%) |
MTHFR | ||||
TT | 7(7%) | 4(5,88%) | 2(6,89%) | 2(5,12%) |
CT | 42(42%) | 35(51,47%) | 14(48,27%) | 21(53,84%) |
CC | 51(51%) | 29(42,65%) | 13(44,84%) | 16(41,04%) |
TPA | ||||
DD | 18(18%) | 13(19,12%) | 3(10,34%) | 10(25,64%)a |
ID | 37(37%) | 38(55,88%)b | 17(58,62%) | 21(53,84%)c |
II | 45(45%) | 17(25%) | 9(31,04%) | 8(20,52%) |